Meningitis vaccine indications and usage

Jump to navigation Jump to search
Meningitis vaccine
MENVEO® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Indications And Usage

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. MENVEO is approved for use in persons 2 months through 55 years of age.

MENVEO does not prevent N. meningitidis serogroup B infections.[1]


References

  1. "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a". External link in |title= (help)

Adapted from the FDA Package Insert.